Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

被引：2

作者：

Jindy, Tanya

Jiang, Cindy Y.

Alhalabi, Omar

Nguyen, Charles B.

Nizam, Amanda

Basu, Arnab

Bilen, Mehmet Asim

Zakharia, Yousef

Milowsky, Matthew I.

Brown, Jason R.

Kilari, Deepak

Emamekhoo, Hamid

Hoimes, Christopher J.

Khaki, Ali Raza

Gupta, Shilpa

Grivas, Petros

Bellmunt, Joaquim

Campbell, Matthew T.

Alva, Ajjai Shivaram

Koshkin, Vadim S.

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA

[4] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA

[5] Cleveland Clin, Cleveland, OH USA

[6] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA

[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[11] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA

[12] Univ Wisconsin, Madison, WI USA

[13] Duke Univ, Duke Canc Inst, Durham, NC USA

[14] Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA USA

[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[16] Univ Washington, Div Hematol & Oncol, Seattle, WA USA

[17] Fred Hutchinson Canc Ctr, Seattle, WA USA

[18] Dana Farber Canc Inst, Boston, MA USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA

[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-183-138-12099; 261-492-3532-2370-7650-2700; 261-566-9263; 4; 2; 3224; 3; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.652

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：652 / 652

页数：1

共 50 条

[21] Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
Furubayashi, Nobuki
Negishi, Takahito
Mochida, Manabu
Kijima, Atsuhiro
Katsuki, Harumichi
Nakamura, Motonobu
IN VIVO, 2025, 39 (01): : 411 - 418
[22] Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin
Curran, Catherine
Adib, Elio
Kazakova, Vera
Grivas, Petros
Diamantopoulos, Leonidas Nikolaos
Alva, Ajjai Shivaram
Su, Christopher
Jain, Rohit K.
Tandon, Ankita
Necchi, Andrea
Marandino, Laura
Plastini, Trisha M.
Merchan, Jaime R.
Sonpavde, Guru
CLINICAL GENITOURINARY CANCER, 2022, 20 (01) : 11 - 16
[23] Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Hanna, Kirollos S.
DRUGS, 2020, 80 (01) : 1 - 7
[24] Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
Wu, Qiuji
Qin, Yi
Liao, Weiting
Zhang, Mengxi
Yang, Yang
Zhang, Pengfei
Li, Qiu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[25] Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE
Nizam, A.
Zhang, L.
Jiang, C. Y.
Nguyen, C. B.
Bakaloudi, D. R.
Bilen, M. A.
Barata, P. M. Coelho
Zakharia, Y.
Milowsky, M. I.
Kilari, D.
Hoimes, C. J.
Khaki, A. R.
Emamekhoo, H.
Gupta, S.
Grivas, P.
Bellmunt, J.
Alva, A. S.
Campbell, M. T.
Alhalabi, O.
Koshkin, V. S.
ANNALS OF ONCOLOGY, 2024, 35 : S1142 - S1142
[26] Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Kirollos S. Hanna
Drugs, 2020, 80 : 1 - 7
[27] Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin
Jindal, Tanya
Zhang, Li
Deshmukh, Prianka
Reyes, Kevin
Chan, Emily
Kumar, Vipul
Zhu, Xiaolin
Maldonado, Edward
Feng, Stephanie
Johnson, Michelle
Angelidakis, Austin
Kwon, Daniel
Desai, Arpita
Borno, Hala T.
Bose, Rohit
Wong, Anthony
Hong, Julian
Carroll, Peter
Meng, Maxwell
Porten, Sima
Aggarwal, Rahul
Small, Eric J.
Fong, Lawrence
Chou, Jonathan
Friedlander, Terence
de Kouchkovsky, Ivan
Koshkin, Vadim S.
CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : e394 - e404
[28] FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Chang, Elaine
Weinstock, Chana
Zhang, Lijun
Charlab, Rosane
Dorff, Sarah E.
Gong, Yutao
Hsu, Vicky
Li, Fang
Ricks, Tiffany K.
Song, Pengfei
Tang, Shenghui
Waldron, Peter E.
Yu, Jingyu
Zahalka, Eias
Goldberg, Kirsten B.
Pazdur, Richard
Theoret, Marc R.
Ibrahim, Amna
Beaver, Julia A.
CLINICAL CANCER RESEARCH, 2021, 27 (04) : 922 - 927
[29] Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.
Teo, Min Yuen
Ratna, Neha
Regazzi, Ashley Marie
Zimmerman, Danielle Elise
McHugh, Deaglan Joseph
Laccetti, Andrew Leonard
Xiao Han
Lee, Chung-Han
Aggen, David Henry
Funt, Samuel Aaron
Bajorin, Dean F.
Iyer, Gopa
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[30] Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis
Khosla, Harshit
Bhatt, Sita
Wang, Ming-Jin
Gignac, Gretchen
Mittal, Kriti
Patel, Jasmine
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 941 - 944

← 1 2 3 4 5 →